ADMP - Adamis Pharmaceuticals Corporation

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Currency in USD

Valuation Measures

Market Cap (intraday) 5
42.25M
Enterprise Value 3
34.04M
Trailing P/E
N/A
Forward P/E 1
-4.28
PEG Ratio (5 yr expected) 1
N/A
Price/Sales (ttm)
2.04
Price/Book (mrq)
1.05
Enterprise Value/Revenue 3
1.64
Enterprise Value/EBITDA 6
-1.00

Trading Information

Stock Price History

Beta (5Y Monthly) 1.44
52-Week Change 3-78.27%
S&P500 52-Week Change 322.86%
52 Week High 33.2900
52 Week Low 30.4800
50-Day Moving Average 30.6836
200-Day Moving Average 30.8209

Share Statistics

Avg Vol (3 month) 31.7M
Avg Vol (10 day) 3527.5k
Shares Outstanding 561.63M
Float 60.1M
% Held by Insiders 11.44%
% Held by Institutions 114.55%
Shares Short (Dec 30, 2019) 46.45M
Short Ratio (Dec 30, 2019) 46.22
Short % of Float (Dec 30, 2019) 413.74%
Short % of Shares Outstanding (Dec 30, 2019) 410.46%
Shares Short (prior month Nov 28, 2019) 46.62M

Dividends & Splits

Forward Annual Dividend Rate 4N/A
Forward Annual Dividend Yield 4N/A
Trailing Annual Dividend Rate 3N/A
Trailing Annual Dividend Yield 3N/A
5 Year Average Dividend Yield 4N/A
Payout Ratio 40.00%
Dividend Date 3N/A
Ex-Dividend Date 4N/A
Last Split Factor 21:17
Last Split Date 3Dec 12, 2013

Financial Highlights

Fiscal Year

Fiscal Year Ends Dec 30, 2018
Most Recent Quarter (mrq)Sep 29, 2019

Profitability

Profit Margin -175.77%
Operating Margin (ttm)-178.29%

Management Effectiveness

Return on Assets (ttm)-37.54%
Return on Equity (ttm)-74.26%

Income Statement

Revenue (ttm)20.73M
Revenue Per Share (ttm)0.42
Quarterly Revenue Growth (yoy)54.00%
Gross Profit (ttm)5.29M
EBITDA -34.08M
Net Income Avi to Common (ttm)-36.43M
Diluted EPS (ttm)-0.7340
Quarterly Earnings Growth (yoy)N/A

Balance Sheet

Total Cash (mrq)12.12M
Total Cash Per Share (mrq)0.2
Total Debt (mrq)4.26M
Total Debt/Equity (mrq)10.56
Current Ratio (mrq)1.69
Book Value Per Share (mrq)0.65

Cash Flow Statement

Operating Cash Flow (ttm)-29.22M
Levered Free Cash Flow (ttm)-17.46M